Ketek (telithromycin), an antibiotic used to combat pneumonia, as well as treating bronchitis and sinusitis, got an unfavorable review from an FDA Advisory Committee (panel) yesterday. Ketek's pneumonia indication may soon come with a 'black box' warning, while its approval for the treatment of sinusitis and bronchitis will go altogether if the FDA does what the panel recommends. The FDA generally does what the panel advises. [click link for full article]
(more...)